Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

And the most innovative biotechnology and pharma products are…

By Brian Buntz | October 31, 2022

Galien FoundationThe Galien Foundation has selected Regeneron’s (Nasdaq:REGN) Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) as the best biotechnology product of 2022 and Amgen’s (Nasdaq:AMGN) Lumakras as the best pharmaceutical agent.

The organization announced the news last week as part of the Prix Galien USA 2022 awards series in a ceremony in New York City.

The antibody cocktail Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) became the first FDA-approved treatment for Ebola (Zaire Ebolavirus) for pediatric and adult patients in 2020.

The Tarrytown, New York–based biotechnology company Regeneron developed Inmazeb with its proprietary VelocImmune mouse technology to facilitate the immediate generation of genetically altered mice from modified embryonic stem cells. In addition, the technique enabled the company to study the drug preclinically without breeding multiple generations of mice.

“Our groundbreaking ‘rapid response’ application of our VelociSuite® technologies to address the Ebola outbreak laid the foundation for our COVID-19 efforts,” said Christos Kyratsous, senior vice president of research, at Regeneron, in a news release.

More about Amgen’s Lumakras

FDA approved Lumakras (sotorasib) for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in 2021, making it the first KRAS protein inhibitor to win regulatory backing. The agency approved the drug using its Accelerated Approval pathway.

Sotorasib has an indication for NSCLC patients with a genetic mutation known as KRAS G12C who have received at least one prior systemic therapy. The KRAS G12C mutation is involved in roughly 13% of mutations in NSCLC, according to the FDA.

Thousand Oaks, California–based Amgen is also exploring sotorasib’s potential for brain metastases, pancreatic cancer, solid tumors and colorectal cancer.

In 2021, Amgen released data for a Phase 2 study of sotorasib known as Codebreak, revealing that key metrics aligned with expectations. At the time, UBS noted that the data supported the drug’s safety and efficacy profile, concluding that the drug should “become the standard of care in 2L+ KRAS+ve NSCLC.”

While some analysts project that sotorasib will have peak sales of approximately $2 billion, UBS anticipated in 2021 that the drug would fetch half as much. In addition, the analyst firm noted that the KRAS G12C mutation involves approximately 13% of non-squamous non-small cell lung cancer rather than 13% of all non-small cell lung cancer.

GlobalData reached similar conclusions, projecting that Lumakras would achieve $1.1 billion in sales by 2029.

Neither Lumakras or Inmazeb appeared in our roundup of best-selling drugs in 2021.


Filed Under: Biologics, Infectious Disease, Oncology
Tagged With: Amgen, Galien Foundation, Regeneron
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
Sanofi ramps up distribution of Beyfortus ahead of RSV season
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE